Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00938158 · ClinicalTrials.gov registry record · Phase 1

A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.

A Phase 1 study, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 1
Development phase
75
Enrollment target

NCT00938158: Completed Phase 1 study, sponsored by GlaxoSmithKline.

NCT00938158 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 75 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00938158, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 1
Development phase
75 participants
Enrollment target

Study Summary

The purpose of this study is to assess the pharmacokinetics and safety of a single subcutaneously injected dose of albiglutide in subjects with type 2 diabetes mellitus with varying degrees of renal function, including subjects requiring hemodialysis.

Interventions

  • BIOLOGICAL albiglutide

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2009-08-05
Est. Completion 2011-04-12
Phase Phase 1
GlaxoSmithKline

1,345 total trials

What the finished NCT00938158 record still lists

NCT00938158 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% higher).

The record links to 0 conditions, and to 1 intervention - of which albiglutide is the first listed.

NCT00938158 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00938158 about?

NCT00938158 is a clinical study titled "A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.". The purpose of this study is to assess the pharmacokinetics and safety of a single subcutaneously injected dose of albiglutide in subjects with type 2 diabetes mellitus with varying degrees of renal function, including subjects requiring hemodialysis.

What is the current status of trial NCT00938158?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2009-08-05. Estimated completion is 2011-04-12.

What interventions are being tested in trial NCT00938158?

The interventions under investigation include: albiglutide (BIOLOGICAL).

Who is sponsoring clinical trial NCT00938158?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00938158's enrollment target sits among peer trials

75 711th of 2000 higher than 1,276 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01535430 · 75 participants

    Assessment of Eloquent Function in Brain Tumor Patients

  • NCT01542879 · 75 participants · Phase 1

    Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

  • NCT02232191 · 75 participants · Phase 2

    Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

  • NCT02754544 · 75 participants · NA

    Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00938158, the US trial registry maintained by the National Library of Medicine. NCT00938158 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.